Jefferies cuts price target on Telix Pharmaceuticals following quarterly update

** Jefferies cuts its price target on Telix Pharmaceuticals TLX.AX to A$31.50 from A$32 and maintains "buy" rating following the company's Q3 update

** Brokerage cuts FY27 NPAT forecast to $2 million from $5 million

** Says uncertainty around the timing of its kidney cancer imaging candidate Zircaix resubmission to US FDA continues to limit near-term valuation upside

** Jefferies notes FY26 revenue guidance of $950 million to $970 million remains unchanged

** 12 of 13 analysts rate the stock 'buy' or higher and one 'hold' with a median price target of A$22.00 - LSEG-compiled data

** YTD, stock up 29.6%, as of last close